Moderna CEO Stéphane Bancel defended the company's plans to raise the price of its Covid vaccine at a Senate hearing Wednesday, saying the move was necessary because its government funding will ...
Moderna is working to cut costs as its Covid-19 vaccine sales fade after years of beefed-up research and development spending during the pandemic, but still wants to come out of the spending cuts ...
Stéphane Bancel, chief executive of Moderna, had a good year in 2022, exercising stock options that netted him nearly $393 million. The company decided his pay wasn’t good enough. The Cambridge ...
Pfizer Inc. and Moderna Inc. have raised the prices of their COVID-19 vaccines in their latest European Union supply contracts, the Financial Times reported on Sunday. The new price for the Pfizer ...
The company saw a drop in interest in Covid-19 vaccines and barely beat its 2023 vaccine sales outlook. Now, Moderna is preparing for a push into new markets starting in 2024.
Moderna Inc. said Tuesday it’s working to develop its first bacterial vaccine to protect against Lyme disease, the tick-borne illness that causes a range of painful symptoms, including fever ...
The US Food and Drug Administration (FDA) approved the latest versions of COVID-19 vaccines developed by Pfizer and Moderna which target newer variants of the SARS-CoV-2 virus, it was announced ...
Editor's Note: The story has been updated with Stéphane Bancel's 2023 compensation based on grant date fair value instead of target value. Despite Moderna’s efforts to prove its mRNA thesis ...
Pfizer, Inc. on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, driving shares down 9% to a 10-year low. Moderna says its updated coronavirus ...
Moderna (MRNA) posted a fourth-quarter profit after beating revenue and earnings estimates. COVID-19 vaccine sales fell by nearly 43% year-over-year. Yahoo Finance Health Reporter Anjalee Khemlani ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window At first glance, these stories appear to be reporting ...
LONDON: Pfizer Inc and Moderna Inc have raised the prices of their COVID-19 vaccines in their latest European Union supply contracts, the Financial Times reported ...